Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Meeting To Examine Human Behavior And The Threat Of Disease
As swine flu spread from Mexico to Texas and then fanned out farther in the United States, Americans began to alter their behavior. Families kept children home from school, postponed trips to the mall, and stayed home instead of eating out. In so doing, the American population may have inadvertently altered the behavior of the pathogen itself.
generic viagra online
DOR BioPharma Receives EMEA Agreement On The Design Of Its Confirmatory Phase 3 Clinical Trial Of OrBec(R) In GI GVHD
DOR BioPharma, Inc. (DOR or the Company) (OTC Bulletin Board: DORB), a late-stage biopharmaceutical company, announced that it has received Protocol Assistance feedback from the European Medicines Agency (EMEA) on the design of its confirmatory, pivotal, Phase 3 clinical trial evaluating its lead product orBec(R) for the treatment of acute gastrointestinal Graft-versus-Host Disease (GI GVHD).
News of the day
Meda: Onsolis Receives FDA Approval
The U.S. Food and Drug Administration (FDA) has approved Onsolis (fentanyl buccal soluble film). This new and patented product is indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Onsolis uses a unique delivery system designed to give rapid and reliable delivery of fentanyl. The product consists of a small dissolvable disc for application of fentanyl to the buccal (inner lining of cheek) membranes. The product is unique and offers an important step to a better pain treatment of cancer patients.
Diagnostics

Revealing A Surprising Link Between Diabetes And Alzheimer's Disease

Blindness, heart disease, nerve damage, and kidney failure are not the only complications facing the nation"s estimated 24 million people with diabetes. Although not widely known, those with the disease face up to double the risk of developing Alzheimer"s disease (AD) than non-diabetics, according to an article scheduled for the May 18 issue of Chemical & Engineering News, ACS" weekly newsmagazine. C&EN senior editor Sophie Rovner explains in the article that people with diabetes tend to have a higher risk of getting AD, and possibly get it at an earlier age, than the general population. Five million people in the United States have Alzheimer"s, a brain disorder that causes severe memory loss. Diabetes results from the body"s inability to produce or use insulin. Newer research now suggests that insulin is critical for healthy nerve cells in the brain. As the hormone declines in the brains of people with Alzheimer"s, so does their memory. Some research even suggests that diabetes and Alzheimer"s are part of the same disease process that affects different parts of the body and that Alzheimer"s may be considered "Type 3" diabetes. If so, then doctors might treat Alzheimer"s in the same way as diabetes, which includes giving patients insulin or other medications - including so-called "insulin sensitizing" drugs - the article states. American Chemical Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009